


Powered by the Sharekhan 3R Research Philosophy



ESG D	NEW			
	SK RATII Aug 08, 2023			12.92
Low F	Risk			
NEGL	LOW	MED	HIGH	SEVERE
0-10 10-20 20-30 30-40				40+
Source: Morningstar				


## Company details

Company details	
Market cap:	Rs. 3,32,166 cr
52-week high/low:	Rs. 1,311 / 945
NSE volume: (No of shares)	25.1 lakh
BSE code:	532281
NSE code:	HCLTECH
Free float: (No of shares)	106.6 cr

### Shareholding (%)

Promoters	60.8
FII	19.0
DII	15.3
Others	4.9

## **Price chart**



### Price performance

Sharekhan Research, Bloomberg

(%)	1m	3m	6m	12m
Absolute	-4.5	6.3	14.2	24.6
Relative to Sensex	-3.3	5.8	4.3	8.6

## **HCL Technologies Ltd**

## Healthy Q2; deal wins strong but revenue guidance lowered

IT & ITES			Sharekhan code: HCLTECH				
Reco/View: Buy		$\leftrightarrow$	CMP: <b>Rs. 1,224</b> Pric			Price Target: Rs. 1,400	<b>1</b>
	<b>1</b>	Upgrade	↔ Maintain ↓ Downgrade				

### Summary

- Q2FY24 numbers were healthy with broadly in-line CC revenue growth of 1% q-o-q and beat of 78 bps in EBIT margin at 18.5%. PAT of Rs. 3,832 crore (up 10% q-o-q) was 5% above our estimate.
- Organic CC revenues grew by 0.5% q-o-q and 0.5% growth was contributed from ASAP acquisition. EBIT
  margin improvement was led by higher utilization, reduced subcontractor costs and lower discretionary
  expenses.
- New deal win TCVs grew strongly by 154% q-o-q to ~\$4 billion. However, management lowered its FY24 CC revenue growth (including ASAP acquisition) guidance to 5-6% (versus 6-8% earlier) given H1 performance and maintained an EBIT margin guidance of 18-19%. Revised revenue growth guidance implies 3.3-4.5% CQGR for Q3/Q4 of FY24. Services CC revenue growth to be in 2.6-3.8% range for Q3/ Q4 of FY24.
- We maintain a Buy on HCL Tech with revised PT of Rs. 1,400 (increase in PT reflects rollover of valuation multiple to FY26E EPS) given robust deal wins and reasonable valuation of 19.4x/17.5x FY25E/FY26E EPS.

HCL Tech reported constant currency (CC) revenue growth of 1% q-o-q (broadly in-line with our estimate of 1.1%) led by healthy CC growth of 1.6% for Services business (IT services/ERS CC revenue growth of 0.9%/5% q-o-q) while Software revenues in cc terms fell by 4% q-o-q (up 3.6% q-o-q). Revenue stood at \$3,225 million, up 0.8 % q-o-q/4.6% y-o-y and revenue in rupee terms stood at Rs. 26,672 crore, up 1.4% q-o-q/ up 8% y-o-y. EBIT margin of 18.5% (up 154 bps q-o-q) was 78 bps above our estimate of 17.7% and a sequential improvement reflects higher utilisation, reduced subcontractor cost (70bps benefit) and cut in discretionary expenses like travel (50bps benefit). Net profit stood at Rs. 3,832 crore (up 8.4% q-o-q; up 9.8% y-o-y) and was 5% above our estimate of Rs3,655 crore. The new deal wins TCV increased strongly by 154% q-o-q to \$3,969 million and much higher-than-normal quarterly run-rate of \$2-2.5 billion. Financial services/Retail & CPG/telecom & media/ Lifesciences & healthcare/public services vertical revenue grew by 1.7%/7.5%/6.2%/1.6%/0.9% q-o-q in CC terms, while that of manufacturing/telecom vertical declined by 1.5%/0.4% q-o-q. Net headcount additions declined by 2,299, taking total headcount to 221,139 while LTM attrition rate significantly declined to 14.2% (versus 16.3% in Q1FY24).

#### **Key positives**

- Strong growth of 154% q-o-q in new deal wins TCV to \$ 4 billion.
- Beat of 78 bps in EBITDA margin at 18.5%, up 154 bps q-o-q.
- LTM attrition further moderated to 14.2% versus 16.3% in Q1FY24.

### Key negatives

• Lowered FY24 CC revenue growth guidance to 5-6% versus earlier guidance of 6-8%.

### **Management Commentary**

- FY24 company CC revenue growth (including ASAP acquisition) guidance lowered to 5-6% (versus 6-8% earlier). Organic company CC revenue growth guidance of 4-5% and Services organic CC revenue growth guidance of 4.5-5.5%.
- EBIT margin guidance maintained at 18-19% for FY24.
- Discretionary spending by clients lagged expectations and still not close to the levels it used to be earlier.
- Pipeline of booking continues to remain strong and its 10% below peak level given robust bookings seen in Q2FY24.
- The company will go ahead with pay revision with effect from October 1, 2023 for 90% of its employees and expect a 60-65 bps margin impact from pay revision.

**Revision in estimates** – We fine-tuned our FY24-25 earnings estimate and have introduced our FY26 earnings estimate in this report.

### Our Cal

**Valuation – Maintain Buy with revised PT of Rs. 1,400:** The management expects revival in H2FY24 given ramp-up of large deal, seasonality benefit for software in Q3 and some recovery in discretionary spending by clients. We estimate healthy revenue/PAT CAGR of 8%/9% over FY23-26E. The stock trades at a reasonable valuation of 19.4x/17.5x its FY25E/26E EPS. Hence, we maintain Buy on HCL Tech with revised price target (PT) of Rs 1,400 (increase in PT reflects rollover of valuation multiple to FY26E EPS).

### **Key Risks**

Rupee appreciation and/or adverse cross-currency movements. The contagion effect of banking crisis, macro headwinds and a possible recession in the US are likely to moderate the pace of technology spending.

Valuation (Consolidated)					Rs cr
Particulars	FY22	FY23	FY24E	FY25E	FY26E
Net sales	85,651.0	1,01,456.0	1,07,945.6	1,17,445.0	1,27,666.4
EBITDA Margin (%)	24.0	22.3	22.4	22.8	23.1
Net profit (Rs cr)	13,499.0	14,850.0	15,560.6	17,143.6	18,976.2
% YoY growth	4.3	10.0	4.8	10.2	10.7
EPS (Rs)	49.7	54.7	57.3	63.2	69.9
PER	24.6	22.4	21.3	19.4	17.5
P/B (x)	5.4	5.1	4.8	4.5	4.2
EV/EBITDA	15.9	14.4	13.0	11.3	9.9
ROE (%)	22.1	23.3	23.1	24.0	25.0
ROCE (%)	23.7	26.4	26.9	28.0	29.3

Source: Company; Sharekhan estimates



## **Key Earnings Call Highlights**

- **Revenue guidance lowered; EBIT guidance maintained:** The company has guided for FY24 CC organic revenue growth of 4%-5% y-o-y (vs 6%-8% y-o-y earlier) with services revenue growth expected to be slightly higher between 4.5%-5.5%(vs 6.5%-8.5% y-o-y earlier). The company has guided FY24 CC revenue growth (including ASAP acquisition) of 5%-6%. The company expects FY24 EBIT margin to be between 18%-19%.
- **Geography-wise performance:** Europe, America and RoW grew by 0.8%, 1.4% and 6.1% q-o-q in CC terms respectively in Q2FY24.
- **Net additions disappoint:** LTM attrition significantly declined by 210 bps q-o-q from 14.2% in Q1 to 14.2%. Net addition declined by 2299, taking the total headcount to 221,139.
- Client metric performance: The number of clients in the \$50 million, \$20 million, \$10 million categories increased by 1, 5, and 6 q-o-q, respectively. DSO improved to 61 from 64 in Q1FY2024. Revenue from top five clients increased by 0.8% q-o-q, but declined 4.2% y-o-y.
- **Booking performance:** New deal win TCVs stood at \$3,969 million, up 154%/66% on a q-o-q and y-o-y basis, respectively. The company won 16 large deals, ten of which were in the services sector and six in the software sector. The deal wins were from diverse sectors like life sciences & healthcare, public services, technology & services, manufacturing, financial services, and retail & CPG among others.
- **Robust cash flows:** OCF/FCF was at 151%/142% of net income on LTM basis. Net cash balance at \$2,558 million was up by 6.9% y-o-y.

Results (Consolidated) Rs cr Q2FY24 **02FY23** Q1FY24 Y-o-Y % Q-o-Q % **Particulars** 3,200.0 Revenues (\$ mn) 3.224.7 3,082.1 4.6 0.8 26,672.0 24,686.0 26,296.0 8.0 **Net sales** 1.4 **Direct Costs** 17,013.0 15,849.0 16,936.0 7.3 0.5 **Gross Profit** 8,837.0 9,360.0 9.3 9,659.0 3.2 Research & development 404.0 388.0 394.0 4.1 2.5 SG&A 3,311.0 3,024.0 3,579.0 9.5 -7.5 **EBITDA** 5,944.0 5,425.0 5,387.0 9.6 10.3 Depreciation & amortization 1,010.0 998.0 927.0 1.2 9.0 **EBIT** 4,934.0 4,427.0 4,460.0 11.5 10.6 Forex gain/(loss) -15.0 NA 46.0 -22.0NA 258.0 Other Income 209.0 111.0 88.3 -19.0 5,128.0 4,584.0 4,696.0 11.9 9.2 Tax Provision 1,295.0 1,096.0 1,165.0 18.2 11.2 **Net profit** 3,832.0 3,489.0 3,534.0 9.8 8.4 0.0 0.0 0.0 Reported net profit 3,832.0 3,489.0 3,534.0 9.8 8.4 EPS (Rs) 141 127 13.0 109 8.4 Margin (%) 20.5 180 **EBITDA** 22.3 22.0 31 **FBIT** 18.5 17.9 17.0 57 154 NPM 14.4 14.1 13.4 23 93 25.3 23.9 24.8 134 45 Tax rate

Source: Company; Sharekhan Research




Revenue mix: Geographies, industry verticals, and other operating metrics

B 41 1	Revenues	Contribution	\$ Grow	rth (%)	CC grov	vth (%)
Particulars	(\$ mn)	(%)	Q-o-Q %	Y-o-Y %	Q-o-Q %	Y-o-Y %
Revenues (\$ mn)	3,225	100	0.8	4.6	1.0	6.3
Geographic mix						
Americas	2,080	64.5	0.8	4.1	1.4	3.9
Europe	919	28.5	0.1	8.4	0.8	3.9
RoW	226	7.0	3.7	-4.9	6.1	-3.6
Industry verticals						
Financial services	729	22.6	0.8	14.8	1.7	12.5
Manufacturing	622	19.3	-2.3	5.2	-1.5	3.3
Technology & services	422	13.1	-1.5	-9.2	-0.4	-9.5
Retail & CPG	310	9.6	6.3	9.2	7.5	8.1
Telecommunications, media, publishing & entertainment	258	8.0	6.1	-9.0	6.2	-10.4
Lifesciences & healthcare	564	17.5	0.8	11.0	1.6	9.8
Public services	319	9.9	-0.2	1.5	0.9	1.7
Service line						
IT and business services	2,406	74.6	0.6	6.0	0.9	4.6
Engineering and R&D Services	516	16.0	4.7	-1.5	5.0	-2.0
Products & platforms	319	9.9	-4.1	5.7	-4.0	3.6
Clients Contribution						
Top 5	316	9.8	0.8	-4.2	0.0	0.0
Top 10	555	17.2	0.8	-4.3	0.0	0.0
Top 20	880	27.3	1.1	-0.1	0.0	0.0

Source: Company; Sharekhan Research

# Sharekhan by BNP PARIBAS

## HCL tech' constant-currency revenue growth trend (y-o-y)




Source: Company; Sharekhan Research

## **EBIT** margin trend



Source: Company; Sharekhan Research


### Trend in services (IT+ ERD) EBIT margin



Source: Company; Sharekhan Research


# Sharekhan by BNP PARIBAS

## New deal wins TCVs trend



Source: Company; Sharekhan Research

## **Net headcount addition**



Source: Company; Sharekhan Research



### **Outlook and Valuation**

## ■ Sector View – Persisting multiple global headwinds turning outlook for FY24E uncertain

Owing to multiple global headwinds, the outlook for FY24E looks uncertain, and the recovery could be gradual in the coming quarters. Hence, concerns relating to macroeconomic headwinds are unlikely to abate anytime soon thus restricting any material outperformance for Indian IT companies.


## ■ Company Outlook – Leveraging on core strengths

HCL Technologies has invested aggressively in the fast-growing Mode-2 (a good proxy for digital offering) capabilities, which would help HCL Tech deliver strong revenue growth in the coming years. Given its differentiated position in Infrastructure Management Services (IMS) and strong capabilities in engineering services, HCL Tech is well positioned to maintain its growth momentum in the IT services business (89% of total revenue) going ahead. HCL Tech's strength in digital foundation and application modernisation make it a strong contender for building digital transformation initiatives for clients.

## ■ Valuation – Maintain Buy with revised PT of Rs. 1,400

The management expects revival in H2FY24 given ramp-up of a large deal, seasonality benefit for software in Q3 and some recovery in discretionary spending by clients. We estimate healthy revenue/PAT CAGR of 8%/9% over FY23-26E. The stock trades at a reasonable valuation of 19.4x/17.5x its FY25E/26E EPS. Hence, we maintain Buy on HCL Tech with revised price target (PT) of Rs 1,400 (increase in PT reflects rollover of valuation multiple to FY26E EPS).





Source: Sharekhan Research



## **About company**

HCL Tech is a leading global technology company providing software-led IT solutions, remote infrastructure management, BPO services, and engineering-related services. Further, the company helps global enterprises reimagine and transform their businesses through digital technology transformation. HCL Tech leverages its global network of integrated co-innovation labs and global delivery capabilities to provide holistic multi-service delivery in key industry verticals.

### **Investment theme**

HCL Tech's revenue growth momentum is expected to accelerate, led by several large deal wins in the past few quarters and gradual recovery in infrastructure management services. The company focuses on chasing large deals to capture market share from incumbents in consolidation deals. Being the leader in IMS practices and the third-largest engineering services player globally in revenue, the company is well positioned to win large deal wins. Strong deal wins along with acquisition of select IP products will help the company drive growth going ahead.

### **Key Risks**

1) Continued slowdown in organic revenue growth, 2) integration issues in ongoing M&A activities, especially IP-related transactions, 3) Rupee appreciation and/or adverse cross-currency movements, 4) pressure in renewal of IMS deals, 5) any hostile regulatory visa norms could have an impact on employee expenses, and 6) any major macro issues in developed markets, especially in the US and Europe.

### **Additional Data**

### Key management personnel

Roshni Nadar Malhotra	Chairperson
C Vijay Kumar	Managing Director and CEO
Prateek Aggarwal	Chief Financial Officer
Apparao V V	Chief Human Resources Officer
Kalyan Kumar	Chief Technology Officer and Head, Ecosystems

Source: Company Website

### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Life Insurance Corp of India	4.55
2	Artisan Partners Ltd	2.18
3	Vanguard Group Inc/The	1.60
4	BlackRock Inc	1.49
5	SBI Funds Management Ltd 1.44	
6	ICICI Prudential Asset Management 1.24	
7	HDFC Asset Management Co Ltd	1.13
8	FMR LLC	0.99
9	FIL Ltd	0.75
10	Mirae Asset Global Investments Co	0.72

Source: Bloombera

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

## **Understanding the Sharekhan 3R Matrix**

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
<b>Right Quality</b>	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/ weak realisation environment resulting in margin pressure and detoriating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research



#### **DISCLAIMER**

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. CIN): - U99999MH1995PLC087498. Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Correspondence/Administrative Office: Gigaplex IT Park, Unit No 1001, 10th Floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400 708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669.

Compliance Officer: Ms. Binkle Oza; Tel: 022-62263303; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022-41523200 / 022-69920600.